These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16603598)

  • 1. Prospective trial on topotecan salvage therapy in primary CNS lymphoma.
    Fischer L; Thiel E; Klasen HA; Birkmann J; Jahnke K; Martus P; Korfel A
    Ann Oncol; 2006 Jul; 17(7):1141-5. PubMed ID: 16603598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
    Voloschin AD; Betensky R; Wen PY; Hochberg F; Batchelor T
    J Neurooncol; 2008 Jan; 86(2):211-5. PubMed ID: 17896078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan.
    Fischer L; Thiel E; Klasen HA; Kirchen H; Jahnke K; Korfel A
    Neurology; 2004 May; 62(10):1885-7. PubMed ID: 15159503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
    Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
    Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
    J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
    Yamanaka R
    Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2014 May; 118(1):155-62. PubMed ID: 24584709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
    Reni M; Ferreri AJ
    Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
    Raizer JJ; Rademaker A; Evens AM; Rice L; Schwartz M; Chandler JP; Getch CC; Tellez C; Grimm SA
    Cancer; 2012 Aug; 118(15):3743-8. PubMed ID: 22179954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
    Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
    Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.
    Jahnke K; Thiel E; Martus P; Herrlinger U; Weller M; Fischer L; Korfel A;
    J Neurooncol; 2006 Nov; 80(2):159-65. PubMed ID: 16699873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
    Du S; Fu DB; A Bota D; Kong XT
    CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
    Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
    Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
    Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
    Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.